Approval of MSD’s PREVYMIS™ (letermovir) in Japan triggers
In March the Japanese Ministry of Health, Labor and Welfare (MLHW) granted marketing authorization to MSD for PREVYMIS™ (letermovir)

more ...

18.04.2018 12:00 Uhr

AiCuris and Max Planck Institute of Molecular Physiology
AiCuris and the Max Planck Institute of Molecular Physiology (MPI) in Dortmund, Germany, have entered into a collaborative agreement to identify novel compounds for the treatment of viral and bacterial infections

more ...


AiCuris’ Licensee MSD launches PREVYMIS™ (letermovir) in Germany
AiCuris and MSD celebrate successful partnership in an exclusive media roundtable discussion pointing to the importance of pharma / biotech collaborations in drug development

more ...


Approval of MSD’s PREVYMIS™ (letermovir) by the European Commission triggers the next EUR 30 million milestone payment for AiCuris
EC approval allows for MSD to market this innovative product across Europe

more ...

If you have a media enquiry or further questions regarding public relation activities at AiCuris please contact:

Katja Woestenhemke

AiCuris Anti-infective Cures GmbH
Friedrich-Ebert-Str. 475
42117 Wuppertal

Phone: +49 (0)202 317 63 - 0
Fax: +49 (0)202 317 63 - 1601
E-Mail: info(at)aicuris.com